nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Doxorubicin—prostate cancer	0.174	1	CrCtD
Epirubicin—Topoisomerase Inhibitors—Mitoxantrone—prostate cancer	0.0792	0.309	CiPCiCtD
Epirubicin—Anthracyclines—Doxorubicin—prostate cancer	0.0757	0.295	CiPCiCtD
Epirubicin—AURKA—prostate cancer	0.0737	0.713	CbGaD
Epirubicin—Topoisomerase Inhibitors—Etoposide—prostate cancer	0.0622	0.242	CiPCiCtD
Epirubicin—urinary bladder cancer—prostate cancer	0.0601	0.363	CtDrD
Epirubicin—bone cancer—prostate cancer	0.0576	0.348	CtDrD
Epirubicin—testicular cancer—prostate cancer	0.0478	0.289	CtDrD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—prostate cancer	0.0396	0.154	CiPCiCtD
Epirubicin—Idarubicin—Doxorubicin—prostate cancer	0.0367	0.333	CrCrCtD
Epirubicin—Daunorubicin—Doxorubicin—prostate cancer	0.0367	0.333	CrCrCtD
Epirubicin—Valrubicin—Doxorubicin—prostate cancer	0.0367	0.333	CrCrCtD
Epirubicin—TOP2A—prostate cancer	0.0296	0.287	CbGaD
Epirubicin—DHCR7—Doxorubicin—prostate cancer	0.0192	0.18	CbGbCtD
Epirubicin—YWHAG—Doxorubicin—prostate cancer	0.0192	0.18	CbGbCtD
Epirubicin—AURKA—Doxorubicin—prostate cancer	0.0192	0.18	CbGbCtD
Epirubicin—ABCC1—Abiraterone—prostate cancer	0.0117	0.109	CbGbCtD
Epirubicin—TOP2A—Mitoxantrone—prostate cancer	0.00907	0.0849	CbGbCtD
Epirubicin—TOP2A—Etoposide—prostate cancer	0.00572	0.0535	CbGbCtD
Epirubicin—ABCC1—Conjugated Estrogens—prostate cancer	0.00553	0.0518	CbGbCtD
Epirubicin—ABCC1—Mitoxantrone—prostate cancer	0.00503	0.0471	CbGbCtD
Epirubicin—TOP2A—Doxorubicin—prostate cancer	0.0039	0.0365	CbGbCtD
Epirubicin—ABCC1—Etoposide—prostate cancer	0.00317	0.0297	CbGbCtD
Epirubicin—ABCC1—Docetaxel—prostate cancer	0.0029	0.0272	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—prostate cancer	0.00216	0.0202	CbGbCtD
Epirubicin—CHD1—prostate gland—prostate cancer	0.000749	0.0633	CbGeAlD
Epirubicin—CHD1—seminal vesicle—prostate cancer	0.000633	0.0535	CbGeAlD
Epirubicin—DHCR7—prostate gland—prostate cancer	0.000505	0.0427	CbGeAlD
Epirubicin—CHD1—urethra—prostate cancer	0.000501	0.0424	CbGeAlD
Epirubicin—YWHAG—prostate gland—prostate cancer	0.000463	0.0391	CbGeAlD
Epirubicin—DHCR7—seminal vesicle—prostate cancer	0.000427	0.0361	CbGeAlD
Epirubicin—UGT2B7—prostate gland—prostate cancer	0.000418	0.0354	CbGeAlD
Epirubicin—AURKA—renal system—prostate cancer	0.000411	0.0348	CbGeAlD
Epirubicin—YWHAG—seminal vesicle—prostate cancer	0.000392	0.0331	CbGeAlD
Epirubicin—CHD1—bone marrow—prostate cancer	0.000386	0.0326	CbGeAlD
Epirubicin—PLA2G4A—prostate gland—prostate cancer	0.000346	0.0292	CbGeAlD
Epirubicin—DHCR7—urethra—prostate cancer	0.000338	0.0286	CbGeAlD
Epirubicin—CHD1—testis—prostate cancer	0.00033	0.0279	CbGeAlD
Epirubicin—TOP2A—prostate gland—prostate cancer	0.000328	0.0277	CbGeAlD
Epirubicin—YWHAG—renal system—prostate cancer	0.000316	0.0267	CbGeAlD
Epirubicin—AURKA—bone marrow—prostate cancer	0.000311	0.0263	CbGeAlD
Epirubicin—YWHAG—urethra—prostate cancer	0.00031	0.0262	CbGeAlD
Epirubicin—PLA2G4A—seminal vesicle—prostate cancer	0.000292	0.0247	CbGeAlD
Epirubicin—UGT2B7—renal system—prostate cancer	0.000285	0.0241	CbGeAlD
Epirubicin—AURKA—testis—prostate cancer	0.000266	0.0225	CbGeAlD
Epirubicin—DHCR7—bone marrow—prostate cancer	0.00026	0.022	CbGeAlD
Epirubicin—CHD1—lymph node—prostate cancer	0.000239	0.0202	CbGeAlD
Epirubicin—YWHAG—bone marrow—prostate cancer	0.000239	0.0202	CbGeAlD
Epirubicin—PLA2G4A—renal system—prostate cancer	0.000236	0.0199	CbGeAlD
Epirubicin—PLA2G4A—urethra—prostate cancer	0.000231	0.0196	CbGeAlD
Epirubicin—DHCR7—testis—prostate cancer	0.000222	0.0188	CbGeAlD
Epirubicin—YWHAG—testis—prostate cancer	0.000204	0.0172	CbGeAlD
Epirubicin—ABCC1—prostate gland—prostate cancer	0.000198	0.0167	CbGeAlD
Epirubicin—AURKA—lymph node—prostate cancer	0.000193	0.0163	CbGeAlD
Epirubicin—UGT2B7—testis—prostate cancer	0.000184	0.0156	CbGeAlD
Epirubicin—PLA2G4A—bone marrow—prostate cancer	0.000178	0.0151	CbGeAlD
Epirubicin—TOP2A—bone marrow—prostate cancer	0.000169	0.0143	CbGeAlD
Epirubicin—ABCC1—seminal vesicle—prostate cancer	0.000167	0.0141	CbGeAlD
Epirubicin—Doxorubicin—CBR1—prostate cancer	0.000167	0.152	CrCbGaD
Epirubicin—DHCR7—lymph node—prostate cancer	0.000161	0.0136	CbGeAlD
Epirubicin—Valrubicin—TOP2A—prostate cancer	0.000161	0.147	CrCbGaD
Epirubicin—PLA2G4A—testis—prostate cancer	0.000152	0.0129	CbGeAlD
Epirubicin—YWHAG—lymph node—prostate cancer	0.000148	0.0125	CbGeAlD
Epirubicin—TOP2A—testis—prostate cancer	0.000145	0.0122	CbGeAlD
Epirubicin—ABCC1—urethra—prostate cancer	0.000132	0.0112	CbGeAlD
Epirubicin—Doxorubicin—RALBP1—prostate cancer	0.000118	0.107	CrCbGaD
Epirubicin—PLA2G4A—lymph node—prostate cancer	0.00011	0.00933	CbGeAlD
Epirubicin—TOP2A—lymph node—prostate cancer	0.000105	0.00886	CbGeAlD
Epirubicin—Doxorubicin—AURKA—prostate cancer	0.0001	0.0914	CrCbGaD
Epirubicin—Idarubicin—TOP2A—prostate cancer	9.23e-05	0.0843	CrCbGaD
Epirubicin—TOP2A—Docetaxel—Cabazitaxel—prostate cancer	8.91e-05	0.119	CbGdCrCtD
Epirubicin—ABCC1—testis—prostate cancer	8.71e-05	0.00736	CbGeAlD
Epirubicin—Doxorubicin—AKR1C3—prostate cancer	7.66e-05	0.07	CrCbGaD
Epirubicin—ABCC1—lymph node—prostate cancer	6.31e-05	0.00533	CbGeAlD
Epirubicin—CHD1—Idarubicin—Doxorubicin—prostate cancer	6.3e-05	0.0843	CbGdCrCtD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—prostate cancer	6.3e-05	0.0843	CbGdCrCtD
Epirubicin—TOP2A—Paclitaxel—Cabazitaxel—prostate cancer	6.15e-05	0.0823	CbGdCrCtD
Epirubicin—Doxorubicin—NQO1—prostate cancer	5.74e-05	0.0525	CrCbGaD
Epirubicin—Daunorubicin—TOP2A—prostate cancer	4.95e-05	0.0452	CrCbGaD
Epirubicin—PLA2G4A—Estradiol—Estradiol valerate/Dienogest—prostate cancer	4.93e-05	0.066	CbGdCrCtD
Epirubicin—Daunorubicin—CYP1B1—prostate cancer	4.9e-05	0.0448	CrCbGaD
Epirubicin—AURKA—Fulvestrant—Estradiol—prostate cancer	4.87e-05	0.0652	CbGdCrCtD
Epirubicin—Doxorubicin—NOS3—prostate cancer	4.85e-05	0.0443	CrCbGaD
Epirubicin—AURKA—Teniposide—Etoposide—prostate cancer	4.29e-05	0.0574	CbGdCrCtD
Epirubicin—PLA2G4A—Estradiol—Estramustine—prostate cancer	4.19e-05	0.0561	CbGdCrCtD
Epirubicin—Doxorubicin—TOP2A—prostate cancer	4.02e-05	0.0367	CrCbGaD
Epirubicin—Doxorubicin—CYP1B1—prostate cancer	3.98e-05	0.0364	CrCbGaD
Epirubicin—Daunorubicin—CYP3A5—prostate cancer	3.9e-05	0.0357	CrCbGaD
Epirubicin—PLA2G4A—Estradiol—Estrone—prostate cancer	3.33e-05	0.0446	CbGdCrCtD
Epirubicin—PLA2G4A—Estradiol—Conjugated Estrogens—prostate cancer	2.93e-05	0.0392	CbGdCrCtD
Epirubicin—Daunorubicin—CYP1A1—prostate cancer	2.65e-05	0.0242	CrCbGaD
Epirubicin—TOP2A—Paclitaxel—Docetaxel—prostate cancer	2.55e-05	0.0342	CbGdCrCtD
Epirubicin—PLA2G4A—Estradiol—Ethinyl Estradiol—prostate cancer	2.46e-05	0.033	CbGdCrCtD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—prostate cancer	2.07e-05	0.0277	CbGdCrCtD
Epirubicin—AURKA—Idarubicin—Doxorubicin—prostate cancer	2.07e-05	0.0277	CbGdCrCtD
Epirubicin—TOP2A—Fulvestrant—Estradiol—prostate cancer	1.86e-05	0.0249	CbGdCrCtD
Epirubicin—Daunorubicin—CYP3A4—prostate cancer	1.69e-05	0.0154	CrCbGaD
Epirubicin—TOP2A—Podofilox—Etoposide—prostate cancer	1.64e-05	0.0219	CbGdCrCtD
Epirubicin—TOP2A—Teniposide—Etoposide—prostate cancer	1.64e-05	0.0219	CbGdCrCtD
Epirubicin—TOP2A—Levorphanol—Estrone—prostate cancer	1.62e-05	0.0217	CbGdCrCtD
Epirubicin—Doxorubicin—CYP3A4—prostate cancer	1.37e-05	0.0125	CrCbGaD
Epirubicin—TOP2A—Levorphanol—Estradiol—prostate cancer	1.23e-05	0.0165	CbGdCrCtD
Epirubicin—TOP2A—Methyltestosterone—Ethinyl Estradiol—prostate cancer	1.12e-05	0.015	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—prostate cancer	7.91e-06	0.0106	CbGdCrCtD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—prostate cancer	7.91e-06	0.0106	CbGdCrCtD
Epirubicin—TOP2A—Norethindrone—Ethinyl Estradiol—prostate cancer	7.33e-06	0.0098	CbGdCrCtD
Epirubicin—TOP2A—Levonorgestrel—Ethinyl Estradiol—prostate cancer	5.83e-06	0.0078	CbGdCrCtD
Epirubicin—PLA2G4A—Dexamethasone—Prednisone—prostate cancer	4.82e-06	0.00645	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Prednisone—prostate cancer	4.82e-06	0.00645	CbGdCrCtD
Epirubicin—TOP2A—Methyltestosterone—Prednisone—prostate cancer	3.95e-06	0.00528	CbGdCrCtD
Epirubicin—Infection—Docetaxel—prostate cancer	3.51e-06	7.66e-05	CcSEcCtD
Epirubicin—Weight decreased—Doxorubicin—prostate cancer	3.51e-06	7.66e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Etoposide—prostate cancer	3.5e-06	7.65e-05	CcSEcCtD
Epirubicin—Hyperglycaemia—Doxorubicin—prostate cancer	3.5e-06	7.64e-05	CcSEcCtD
Epirubicin—Diarrhoea—Mitoxantrone—prostate cancer	3.5e-06	7.64e-05	CcSEcCtD
Epirubicin—Dry mouth—Capecitabine—prostate cancer	3.49e-06	7.62e-05	CcSEcCtD
Epirubicin—Vomiting—Estradiol—prostate cancer	3.49e-06	7.62e-05	CcSEcCtD
Epirubicin—Pneumonia—Doxorubicin—prostate cancer	3.48e-06	7.59e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Etoposide—prostate cancer	3.48e-06	7.59e-05	CcSEcCtD
Epirubicin—Shock—Docetaxel—prostate cancer	3.48e-06	7.59e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Docetaxel—prostate cancer	3.47e-06	7.57e-05	CcSEcCtD
Epirubicin—Ill-defined disorder—Prednisone—prostate cancer	3.47e-06	7.56e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Docetaxel—prostate cancer	3.46e-06	7.55e-05	CcSEcCtD
Epirubicin—Rash—Estradiol—prostate cancer	3.46e-06	7.55e-05	CcSEcCtD
Epirubicin—Infestation—Doxorubicin—prostate cancer	3.46e-06	7.55e-05	CcSEcCtD
Epirubicin—Infestation NOS—Doxorubicin—prostate cancer	3.46e-06	7.55e-05	CcSEcCtD
Epirubicin—Drowsiness—Doxorubicin—prostate cancer	3.46e-06	7.55e-05	CcSEcCtD
Epirubicin—Dermatitis—Estradiol—prostate cancer	3.46e-06	7.55e-05	CcSEcCtD
Epirubicin—Anaemia—Prednisone—prostate cancer	3.45e-06	7.54e-05	CcSEcCtD
Epirubicin—Confusional state—Capecitabine—prostate cancer	3.45e-06	7.53e-05	CcSEcCtD
Epirubicin—Tachycardia—Docetaxel—prostate cancer	3.45e-06	7.53e-05	CcSEcCtD
Epirubicin—Headache—Estradiol—prostate cancer	3.44e-06	7.5e-05	CcSEcCtD
Epirubicin—Skin disorder—Docetaxel—prostate cancer	3.43e-06	7.49e-05	CcSEcCtD
Epirubicin—Agitation—Prednisone—prostate cancer	3.43e-06	7.49e-05	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	3.43e-06	7.49e-05	CcSEcCtD
Epirubicin—Oedema—Capecitabine—prostate cancer	3.42e-06	7.47e-05	CcSEcCtD
Epirubicin—Renal failure—Doxorubicin—prostate cancer	3.4e-06	7.42e-05	CcSEcCtD
Epirubicin—Infection—Capecitabine—prostate cancer	3.4e-06	7.42e-05	CcSEcCtD
Epirubicin—Neuropathy peripheral—Doxorubicin—prostate cancer	3.39e-06	7.4e-05	CcSEcCtD
Epirubicin—Urticaria—Etoposide—prostate cancer	3.38e-06	7.38e-05	CcSEcCtD
Epirubicin—Stomatitis—Doxorubicin—prostate cancer	3.37e-06	7.36e-05	CcSEcCtD
Epirubicin—Jaundice—Doxorubicin—prostate cancer	3.37e-06	7.36e-05	CcSEcCtD
Epirubicin—Anorexia—Docetaxel—prostate cancer	3.37e-06	7.35e-05	CcSEcCtD
Epirubicin—Malaise—Prednisone—prostate cancer	3.37e-06	7.35e-05	CcSEcCtD
Epirubicin—Shock—Capecitabine—prostate cancer	3.37e-06	7.35e-05	CcSEcCtD
Epirubicin—Abdominal pain—Etoposide—prostate cancer	3.36e-06	7.34e-05	CcSEcCtD
Epirubicin—Body temperature increased—Etoposide—prostate cancer	3.36e-06	7.34e-05	CcSEcCtD
Epirubicin—Urinary tract infection—Doxorubicin—prostate cancer	3.36e-06	7.34e-05	CcSEcCtD
Epirubicin—Conjunctivitis—Doxorubicin—prostate cancer	3.36e-06	7.34e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Capecitabine—prostate cancer	3.36e-06	7.33e-05	CcSEcCtD
Epirubicin—Vertigo—Prednisone—prostate cancer	3.36e-06	7.32e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Capecitabine—prostate cancer	3.35e-06	7.31e-05	CcSEcCtD
Epirubicin—Syncope—Prednisone—prostate cancer	3.35e-06	7.31e-05	CcSEcCtD
Epirubicin—Tachycardia—Capecitabine—prostate cancer	3.34e-06	7.29e-05	CcSEcCtD
Epirubicin—Skin disorder—Capecitabine—prostate cancer	3.32e-06	7.26e-05	CcSEcCtD
Epirubicin—Sweating—Doxorubicin—prostate cancer	3.32e-06	7.24e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Capecitabine—prostate cancer	3.31e-06	7.22e-05	CcSEcCtD
Epirubicin—Hypotension—Docetaxel—prostate cancer	3.3e-06	7.21e-05	CcSEcCtD
Epirubicin—Haematuria—Doxorubicin—prostate cancer	3.3e-06	7.2e-05	CcSEcCtD
Epirubicin—Loss of consciousness—Prednisone—prostate cancer	3.28e-06	7.17e-05	CcSEcCtD
Epirubicin—Hepatobiliary disease—Doxorubicin—prostate cancer	3.27e-06	7.14e-05	CcSEcCtD
Epirubicin—Epistaxis—Doxorubicin—prostate cancer	3.26e-06	7.12e-05	CcSEcCtD
Epirubicin—Anorexia—Capecitabine—prostate cancer	3.26e-06	7.12e-05	CcSEcCtD
Epirubicin—Nausea—Estradiol—prostate cancer	3.26e-06	7.12e-05	CcSEcCtD
Epirubicin—Vomiting—Mitoxantrone—prostate cancer	3.25e-06	7.1e-05	CcSEcCtD
Epirubicin—Sinusitis—Doxorubicin—prostate cancer	3.25e-06	7.08e-05	CcSEcCtD
Epirubicin—Convulsion—Prednisone—prostate cancer	3.24e-06	7.06e-05	CcSEcCtD
Epirubicin—Agranulocytosis—Doxorubicin—prostate cancer	3.23e-06	7.05e-05	CcSEcCtD
Epirubicin—Hypertension—Prednisone—prostate cancer	3.22e-06	7.04e-05	CcSEcCtD
Epirubicin—Rash—Mitoxantrone—prostate cancer	3.22e-06	7.04e-05	CcSEcCtD
Epirubicin—Dermatitis—Mitoxantrone—prostate cancer	3.22e-06	7.03e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.22e-06	7.03e-05	CcSEcCtD
Epirubicin—Headache—Mitoxantrone—prostate cancer	3.2e-06	6.99e-05	CcSEcCtD
Epirubicin—Hypotension—Capecitabine—prostate cancer	3.2e-06	6.98e-05	CcSEcCtD
Epirubicin—Insomnia—Docetaxel—prostate cancer	3.2e-06	6.98e-05	CcSEcCtD
Epirubicin—Arthralgia—Prednisone—prostate cancer	3.18e-06	6.94e-05	CcSEcCtD
Epirubicin—Myalgia—Prednisone—prostate cancer	3.18e-06	6.94e-05	CcSEcCtD
Epirubicin—Paraesthesia—Docetaxel—prostate cancer	3.17e-06	6.93e-05	CcSEcCtD
Epirubicin—Anxiety—Prednisone—prostate cancer	3.17e-06	6.92e-05	CcSEcCtD
Epirubicin—Bradycardia—Doxorubicin—prostate cancer	3.16e-06	6.9e-05	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.16e-06	6.89e-05	CcSEcCtD
Epirubicin—Dyspnoea—Docetaxel—prostate cancer	3.15e-06	6.88e-05	CcSEcCtD
Epirubicin—Somnolence—Docetaxel—prostate cancer	3.14e-06	6.86e-05	CcSEcCtD
Epirubicin—Discomfort—Prednisone—prostate cancer	3.14e-06	6.86e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Etoposide—prostate cancer	3.13e-06	6.84e-05	CcSEcCtD
Epirubicin—Haemoglobin—Doxorubicin—prostate cancer	3.12e-06	6.81e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.12e-06	6.81e-05	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—prostate cancer	3.11e-06	6.79e-05	CcSEcCtD
Epirubicin—Dyspepsia—Docetaxel—prostate cancer	3.11e-06	6.79e-05	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—prostate cancer	3.11e-06	6.78e-05	CcSEcCtD
Epirubicin—Hepatitis—Doxorubicin—prostate cancer	3.11e-06	6.78e-05	CcSEcCtD
Epirubicin—Insomnia—Capecitabine—prostate cancer	3.1e-06	6.76e-05	CcSEcCtD
Epirubicin—Hypoaesthesia—Doxorubicin—prostate cancer	3.09e-06	6.74e-05	CcSEcCtD
Epirubicin—Pharyngitis—Doxorubicin—prostate cancer	3.08e-06	6.73e-05	CcSEcCtD
Epirubicin—Paraesthesia—Capecitabine—prostate cancer	3.07e-06	6.71e-05	CcSEcCtD
Epirubicin—Decreased appetite—Docetaxel—prostate cancer	3.07e-06	6.71e-05	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—prostate cancer	3.07e-06	6.69e-05	CcSEcCtD
Epirubicin—Oedema peripheral—Doxorubicin—prostate cancer	3.06e-06	6.68e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Docetaxel—prostate cancer	3.05e-06	6.66e-05	CcSEcCtD
Epirubicin—Asthenia—Etoposide—prostate cancer	3.05e-06	6.66e-05	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—prostate cancer	3.05e-06	6.66e-05	CcSEcCtD
Epirubicin—Dyspnoea—Capecitabine—prostate cancer	3.05e-06	6.66e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Prednisone—prostate cancer	3.05e-06	6.65e-05	CcSEcCtD
Epirubicin—Oedema—Prednisone—prostate cancer	3.05e-06	6.65e-05	CcSEcCtD
Epirubicin—Fatigue—Docetaxel—prostate cancer	3.05e-06	6.65e-05	CcSEcCtD
Epirubicin—Urethral disorder—Doxorubicin—prostate cancer	3.04e-06	6.64e-05	CcSEcCtD
Epirubicin—Nausea—Mitoxantrone—prostate cancer	3.04e-06	6.63e-05	CcSEcCtD
Epirubicin—Infection—Prednisone—prostate cancer	3.03e-06	6.61e-05	CcSEcCtD
Epirubicin—Pain—Docetaxel—prostate cancer	3.02e-06	6.6e-05	CcSEcCtD
Epirubicin—Constipation—Docetaxel—prostate cancer	3.02e-06	6.6e-05	CcSEcCtD
Epirubicin—Dyspepsia—Capecitabine—prostate cancer	3.01e-06	6.58e-05	CcSEcCtD
Epirubicin—Pruritus—Etoposide—prostate cancer	3.01e-06	6.57e-05	CcSEcCtD
Epirubicin—Shock—Prednisone—prostate cancer	3e-06	6.55e-05	CcSEcCtD
Epirubicin—Visual impairment—Doxorubicin—prostate cancer	2.99e-06	6.53e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Prednisone—prostate cancer	2.99e-06	6.53e-05	CcSEcCtD
Epirubicin—Tachycardia—Prednisone—prostate cancer	2.98e-06	6.49e-05	CcSEcCtD
Epirubicin—Decreased appetite—Capecitabine—prostate cancer	2.97e-06	6.49e-05	CcSEcCtD
Epirubicin—Skin disorder—Prednisone—prostate cancer	2.96e-06	6.46e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Capecitabine—prostate cancer	2.95e-06	6.45e-05	CcSEcCtD
Epirubicin—Fatigue—Capecitabine—prostate cancer	2.95e-06	6.44e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Prednisone—prostate cancer	2.95e-06	6.43e-05	CcSEcCtD
Epirubicin—Erythema multiforme—Doxorubicin—prostate cancer	2.94e-06	6.41e-05	CcSEcCtD
Epirubicin—Constipation—Capecitabine—prostate cancer	2.93e-06	6.39e-05	CcSEcCtD
Epirubicin—Pain—Capecitabine—prostate cancer	2.93e-06	6.39e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Docetaxel—prostate cancer	2.91e-06	6.36e-05	CcSEcCtD
Epirubicin—Diarrhoea—Etoposide—prostate cancer	2.91e-06	6.35e-05	CcSEcCtD
Epirubicin—Anorexia—Prednisone—prostate cancer	2.91e-06	6.34e-05	CcSEcCtD
Epirubicin—Eye disorder—Doxorubicin—prostate cancer	2.9e-06	6.33e-05	CcSEcCtD
Epirubicin—Tinnitus—Doxorubicin—prostate cancer	2.9e-06	6.32e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Docetaxel—prostate cancer	2.89e-06	6.31e-05	CcSEcCtD
Epirubicin—Flushing—Doxorubicin—prostate cancer	2.88e-06	6.29e-05	CcSEcCtD
Epirubicin—Cardiac disorder—Doxorubicin—prostate cancer	2.88e-06	6.29e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Capecitabine—prostate cancer	2.82e-06	6.16e-05	CcSEcCtD
Epirubicin—Angiopathy—Doxorubicin—prostate cancer	2.82e-06	6.15e-05	CcSEcCtD
Epirubicin—Dizziness—Etoposide—prostate cancer	2.81e-06	6.14e-05	CcSEcCtD
Epirubicin—Immune system disorder—Doxorubicin—prostate cancer	2.8e-06	6.12e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Capecitabine—prostate cancer	2.8e-06	6.11e-05	CcSEcCtD
Epirubicin—Mediastinal disorder—Doxorubicin—prostate cancer	2.8e-06	6.11e-05	CcSEcCtD
Epirubicin—Abdominal pain—Docetaxel—prostate cancer	2.79e-06	6.1e-05	CcSEcCtD
Epirubicin—Body temperature increased—Docetaxel—prostate cancer	2.79e-06	6.1e-05	CcSEcCtD
Epirubicin—Chills—Doxorubicin—prostate cancer	2.79e-06	6.08e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Prednisone—prostate cancer	2.78e-06	6.06e-05	CcSEcCtD
Epirubicin—Arrhythmia—Doxorubicin—prostate cancer	2.77e-06	6.05e-05	CcSEcCtD
Epirubicin—Insomnia—Prednisone—prostate cancer	2.76e-06	6.02e-05	CcSEcCtD
Epirubicin—Alopecia—Doxorubicin—prostate cancer	2.74e-06	5.99e-05	CcSEcCtD
Epirubicin—Paraesthesia—Prednisone—prostate cancer	2.74e-06	5.97e-05	CcSEcCtD
Epirubicin—Mental disorder—Doxorubicin—prostate cancer	2.72e-06	5.94e-05	CcSEcCtD
Epirubicin—Urticaria—Capecitabine—prostate cancer	2.72e-06	5.93e-05	CcSEcCtD
Epirubicin—Abdominal pain—Capecitabine—prostate cancer	2.71e-06	5.91e-05	CcSEcCtD
Epirubicin—Body temperature increased—Capecitabine—prostate cancer	2.71e-06	5.91e-05	CcSEcCtD
Epirubicin—Vomiting—Etoposide—prostate cancer	2.7e-06	5.9e-05	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—prostate cancer	2.7e-06	5.9e-05	CcSEcCtD
Epirubicin—Erythema—Doxorubicin—prostate cancer	2.7e-06	5.9e-05	CcSEcCtD
Epirubicin—Dyspepsia—Prednisone—prostate cancer	2.68e-06	5.86e-05	CcSEcCtD
Epirubicin—Rash—Etoposide—prostate cancer	2.68e-06	5.85e-05	CcSEcCtD
Epirubicin—Dermatitis—Etoposide—prostate cancer	2.68e-06	5.85e-05	CcSEcCtD
Epirubicin—Headache—Etoposide—prostate cancer	2.66e-06	5.82e-05	CcSEcCtD
Epirubicin—Flatulence—Doxorubicin—prostate cancer	2.66e-06	5.81e-05	CcSEcCtD
Epirubicin—Tension—Doxorubicin—prostate cancer	2.65e-06	5.79e-05	CcSEcCtD
Epirubicin—Decreased appetite—Prednisone—prostate cancer	2.65e-06	5.78e-05	CcSEcCtD
Epirubicin—Dysgeusia—Doxorubicin—prostate cancer	2.65e-06	5.78e-05	CcSEcCtD
Epirubicin—Fatigue—Prednisone—prostate cancer	2.63e-06	5.74e-05	CcSEcCtD
Epirubicin—Nervousness—Doxorubicin—prostate cancer	2.63e-06	5.73e-05	CcSEcCtD
Epirubicin—Back pain—Doxorubicin—prostate cancer	2.61e-06	5.71e-05	CcSEcCtD
Epirubicin—Constipation—Prednisone—prostate cancer	2.61e-06	5.69e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Docetaxel—prostate cancer	2.6e-06	5.68e-05	CcSEcCtD
Epirubicin—Muscle spasms—Doxorubicin—prostate cancer	2.6e-06	5.67e-05	CcSEcCtD
Epirubicin—Vision blurred—Doxorubicin—prostate cancer	2.55e-06	5.56e-05	CcSEcCtD
Epirubicin—Asthenia—Docetaxel—prostate cancer	2.54e-06	5.54e-05	CcSEcCtD
Epirubicin—Nausea—Etoposide—prostate cancer	2.53e-06	5.51e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Capecitabine—prostate cancer	2.52e-06	5.5e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Prednisone—prostate cancer	2.51e-06	5.48e-05	CcSEcCtD
Epirubicin—Ill-defined disorder—Doxorubicin—prostate cancer	2.51e-06	5.47e-05	CcSEcCtD
Epirubicin—Pruritus—Docetaxel—prostate cancer	2.5e-06	5.46e-05	CcSEcCtD
Epirubicin—Anaemia—Doxorubicin—prostate cancer	2.5e-06	5.45e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Prednisone—prostate cancer	2.49e-06	5.44e-05	CcSEcCtD
Epirubicin—Agitation—Doxorubicin—prostate cancer	2.48e-06	5.42e-05	CcSEcCtD
Epirubicin—Asthenia—Capecitabine—prostate cancer	2.46e-06	5.36e-05	CcSEcCtD
Epirubicin—Malaise—Doxorubicin—prostate cancer	2.44e-06	5.32e-05	CcSEcCtD
Epirubicin—Vertigo—Doxorubicin—prostate cancer	2.43e-06	5.3e-05	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—prostate cancer	2.42e-06	5.29e-05	CcSEcCtD
Epirubicin—Urticaria—Prednisone—prostate cancer	2.42e-06	5.29e-05	CcSEcCtD
Epirubicin—Pruritus—Capecitabine—prostate cancer	2.42e-06	5.28e-05	CcSEcCtD
Epirubicin—Leukopenia—Doxorubicin—prostate cancer	2.42e-06	5.28e-05	CcSEcCtD
Epirubicin—Diarrhoea—Docetaxel—prostate cancer	2.42e-06	5.28e-05	CcSEcCtD
Epirubicin—Body temperature increased—Prednisone—prostate cancer	2.41e-06	5.26e-05	CcSEcCtD
Epirubicin—Abdominal pain—Prednisone—prostate cancer	2.41e-06	5.26e-05	CcSEcCtD
Epirubicin—Palpitations—Doxorubicin—prostate cancer	2.39e-06	5.21e-05	CcSEcCtD
Epirubicin—Loss of consciousness—Doxorubicin—prostate cancer	2.38e-06	5.19e-05	CcSEcCtD
Epirubicin—Cough—Doxorubicin—prostate cancer	2.36e-06	5.15e-05	CcSEcCtD
Epirubicin—Convulsion—Doxorubicin—prostate cancer	2.34e-06	5.11e-05	CcSEcCtD
Epirubicin—Diarrhoea—Capecitabine—prostate cancer	2.34e-06	5.11e-05	CcSEcCtD
Epirubicin—Dizziness—Docetaxel—prostate cancer	2.34e-06	5.1e-05	CcSEcCtD
Epirubicin—Hypertension—Doxorubicin—prostate cancer	2.33e-06	5.09e-05	CcSEcCtD
Epirubicin—Chest pain—Doxorubicin—prostate cancer	2.3e-06	5.02e-05	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—prostate cancer	2.3e-06	5.02e-05	CcSEcCtD
Epirubicin—Myalgia—Doxorubicin—prostate cancer	2.3e-06	5.02e-05	CcSEcCtD
Epirubicin—Anxiety—Doxorubicin—prostate cancer	2.29e-06	5.01e-05	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.29e-06	4.99e-05	CcSEcCtD
Epirubicin—Discomfort—Doxorubicin—prostate cancer	2.27e-06	4.96e-05	CcSEcCtD
Epirubicin—Dizziness—Capecitabine—prostate cancer	2.26e-06	4.94e-05	CcSEcCtD
Epirubicin—Dry mouth—Doxorubicin—prostate cancer	2.25e-06	4.91e-05	CcSEcCtD
Epirubicin—Vomiting—Docetaxel—prostate cancer	2.25e-06	4.91e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Prednisone—prostate cancer	2.25e-06	4.9e-05	CcSEcCtD
Epirubicin—Rash—Docetaxel—prostate cancer	2.23e-06	4.86e-05	CcSEcCtD
Epirubicin—Dermatitis—Docetaxel—prostate cancer	2.23e-06	4.86e-05	CcSEcCtD
Epirubicin—Confusional state—Doxorubicin—prostate cancer	2.22e-06	4.86e-05	CcSEcCtD
Epirubicin—Headache—Docetaxel—prostate cancer	2.21e-06	4.83e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Doxorubicin—prostate cancer	2.21e-06	4.82e-05	CcSEcCtD
Epirubicin—Oedema—Doxorubicin—prostate cancer	2.21e-06	4.82e-05	CcSEcCtD
Epirubicin—Infection—Doxorubicin—prostate cancer	2.19e-06	4.78e-05	CcSEcCtD
Epirubicin—Asthenia—Prednisone—prostate cancer	2.19e-06	4.77e-05	CcSEcCtD
Epirubicin—Vomiting—Capecitabine—prostate cancer	2.18e-06	4.75e-05	CcSEcCtD
Epirubicin—Shock—Doxorubicin—prostate cancer	2.17e-06	4.74e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Doxorubicin—prostate cancer	2.16e-06	4.72e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Doxorubicin—prostate cancer	2.16e-06	4.71e-05	CcSEcCtD
Epirubicin—Rash—Capecitabine—prostate cancer	2.16e-06	4.71e-05	CcSEcCtD
Epirubicin—Pruritus—Prednisone—prostate cancer	2.16e-06	4.71e-05	CcSEcCtD
Epirubicin—Dermatitis—Capecitabine—prostate cancer	2.16e-06	4.71e-05	CcSEcCtD
Epirubicin—Tachycardia—Doxorubicin—prostate cancer	2.15e-06	4.7e-05	CcSEcCtD
Epirubicin—Headache—Capecitabine—prostate cancer	2.14e-06	4.68e-05	CcSEcCtD
Epirubicin—Skin disorder—Doxorubicin—prostate cancer	2.14e-06	4.68e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Doxorubicin—prostate cancer	2.13e-06	4.65e-05	CcSEcCtD
Epirubicin—Anorexia—Doxorubicin—prostate cancer	2.1e-06	4.59e-05	CcSEcCtD
Epirubicin—Nausea—Docetaxel—prostate cancer	2.1e-06	4.58e-05	CcSEcCtD
Epirubicin—Diarrhoea—Prednisone—prostate cancer	2.09e-06	4.55e-05	CcSEcCtD
Epirubicin—Hypotension—Doxorubicin—prostate cancer	2.06e-06	4.5e-05	CcSEcCtD
Epirubicin—Nausea—Capecitabine—prostate cancer	2.03e-06	4.44e-05	CcSEcCtD
Epirubicin—Dizziness—Prednisone—prostate cancer	2.02e-06	4.4e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.01e-06	4.39e-05	CcSEcCtD
Epirubicin—Insomnia—Doxorubicin—prostate cancer	2e-06	4.36e-05	CcSEcCtD
Epirubicin—Paraesthesia—Doxorubicin—prostate cancer	1.98e-06	4.32e-05	CcSEcCtD
Epirubicin—Dyspnoea—Doxorubicin—prostate cancer	1.97e-06	4.29e-05	CcSEcCtD
Epirubicin—Somnolence—Doxorubicin—prostate cancer	1.96e-06	4.28e-05	CcSEcCtD
Epirubicin—Dyspepsia—Doxorubicin—prostate cancer	1.94e-06	4.24e-05	CcSEcCtD
Epirubicin—Vomiting—Prednisone—prostate cancer	1.94e-06	4.23e-05	CcSEcCtD
Epirubicin—Rash—Prednisone—prostate cancer	1.92e-06	4.2e-05	CcSEcCtD
Epirubicin—Dermatitis—Prednisone—prostate cancer	1.92e-06	4.19e-05	CcSEcCtD
Epirubicin—Decreased appetite—Doxorubicin—prostate cancer	1.92e-06	4.19e-05	CcSEcCtD
Epirubicin—Headache—Prednisone—prostate cancer	1.91e-06	4.17e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.9e-06	4.16e-05	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—prostate cancer	1.9e-06	4.15e-05	CcSEcCtD
Epirubicin—Pain—Doxorubicin—prostate cancer	1.89e-06	4.12e-05	CcSEcCtD
Epirubicin—Constipation—Doxorubicin—prostate cancer	1.89e-06	4.12e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Doxorubicin—prostate cancer	1.82e-06	3.97e-05	CcSEcCtD
Epirubicin—Nausea—Prednisone—prostate cancer	1.81e-06	3.95e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Doxorubicin—prostate cancer	1.8e-06	3.94e-05	CcSEcCtD
Epirubicin—Urticaria—Doxorubicin—prostate cancer	1.75e-06	3.83e-05	CcSEcCtD
Epirubicin—Abdominal pain—Doxorubicin—prostate cancer	1.74e-06	3.81e-05	CcSEcCtD
Epirubicin—Body temperature increased—Doxorubicin—prostate cancer	1.74e-06	3.81e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Doxorubicin—prostate cancer	1.63e-06	3.55e-05	CcSEcCtD
Epirubicin—Asthenia—Doxorubicin—prostate cancer	1.58e-06	3.45e-05	CcSEcCtD
Epirubicin—Pruritus—Doxorubicin—prostate cancer	1.56e-06	3.41e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PTHLH—prostate cancer	1.55e-06	6.51e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.54e-06	6.48e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CYP1B1—prostate cancer	1.54e-06	6.47e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP3A4—prostate cancer	1.54e-06	6.46e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.53e-06	6.43e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKR1C3—prostate cancer	1.52e-06	6.41e-05	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—EP300—prostate cancer	1.52e-06	6.39e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PRKACB—prostate cancer	1.52e-06	6.37e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ACHE—prostate cancer	1.51e-06	6.37e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTT1—prostate cancer	1.51e-06	6.37e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP1B1—prostate cancer	1.51e-06	6.35e-05	CbGpPWpGaD
Epirubicin—Diarrhoea—Doxorubicin—prostate cancer	1.51e-06	3.29e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CYP2A6—prostate cancer	1.5e-06	6.29e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HSPA1A—prostate cancer	1.49e-06	6.27e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GGT1—prostate cancer	1.49e-06	6.27e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.49e-06	6.27e-05	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MYC—prostate cancer	1.48e-06	6.23e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PPP3CA—prostate cancer	1.48e-06	6.21e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—THBS1—prostate cancer	1.48e-06	6.21e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—NCOA1—prostate cancer	1.47e-06	6.18e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GGT1—prostate cancer	1.46e-06	6.15e-05	CbGpPWpGaD
Epirubicin—Dizziness—Doxorubicin—prostate cancer	1.46e-06	3.18e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—ANXA1—prostate cancer	1.46e-06	6.12e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—AKR1C3—prostate cancer	1.46e-06	6.12e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PRKACB—prostate cancer	1.45e-06	6.09e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CYP19A1—prostate cancer	1.45e-06	6.09e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NCOA1—prostate cancer	1.44e-06	6.06e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP17A1—prostate cancer	1.43e-06	6.03e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CASP9—prostate cancer	1.43e-06	6.02e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PRKCZ—prostate cancer	1.43e-06	6.01e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP19A1—prostate cancer	1.42e-06	5.97e-05	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.42e-06	5.96e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.41e-06	5.94e-05	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—prostate cancer	1.4e-06	3.06e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—RXRA—prostate cancer	1.4e-06	5.87e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—EP300—prostate cancer	1.4e-06	5.87e-05	CbGpPWpGaD
Epirubicin—Rash—Doxorubicin—prostate cancer	1.39e-06	3.04e-05	CcSEcCtD
Epirubicin—Dermatitis—Doxorubicin—prostate cancer	1.39e-06	3.03e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—PRKCQ—prostate cancer	1.39e-06	5.83e-05	CbGpPWpGaD
Epirubicin—Headache—Doxorubicin—prostate cancer	1.38e-06	3.02e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—FGFR4—prostate cancer	1.38e-06	5.8e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PARP1—prostate cancer	1.38e-06	5.8e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—RXRA—prostate cancer	1.37e-06	5.76e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NCOA2—prostate cancer	1.37e-06	5.74e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CALCA—prostate cancer	1.36e-06	5.73e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—SRC—prostate cancer	1.36e-06	5.71e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—COMT—prostate cancer	1.35e-06	5.66e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GSTP1—prostate cancer	1.34e-06	5.63e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.33e-06	5.6e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL12—prostate cancer	1.33e-06	5.6e-05	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MYC—prostate cancer	1.32e-06	5.57e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—prostate cancer	1.32e-06	5.56e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—COMT—prostate cancer	1.32e-06	5.55e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ITPR1—prostate cancer	1.32e-06	5.54e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FGF10—prostate cancer	1.32e-06	5.54e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GSTP1—prostate cancer	1.31e-06	5.52e-05	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—prostate cancer	1.31e-06	2.86e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—SLC5A5—prostate cancer	1.3e-06	5.48e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ITPR1—prostate cancer	1.29e-06	5.44e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP2E1—prostate cancer	1.27e-06	5.35e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.27e-06	5.34e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CG—prostate cancer	1.27e-06	5.33e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NQO1—prostate cancer	1.26e-06	5.29e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CASP9—prostate cancer	1.25e-06	5.27e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TGFBR2—prostate cancer	1.25e-06	5.27e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—TYMS—prostate cancer	1.24e-06	5.24e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—TH—prostate cancer	1.24e-06	5.22e-05	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PIK3CA—prostate cancer	1.24e-06	5.2e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ITPR1—prostate cancer	1.23e-06	5.19e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.23e-06	5.18e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GSTM1—prostate cancer	1.23e-06	5.18e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP3A4—prostate cancer	1.23e-06	5.16e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—TYMS—prostate cancer	1.22e-06	5.14e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.22e-06	5.13e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PRKCQ—prostate cancer	1.22e-06	5.11e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NGFR—prostate cancer	1.22e-06	5.11e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TGFB1—prostate cancer	1.21e-06	5.1e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—LPL—prostate cancer	1.21e-06	5.08e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GSTM1—prostate cancer	1.21e-06	5.08e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP1B1—prostate cancer	1.21e-06	5.07e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAP3K7—prostate cancer	1.2e-06	5.05e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—LPL—prostate cancer	1.18e-06	4.98e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GGT1—prostate cancer	1.17e-06	4.91e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CYP1A1—prostate cancer	1.17e-06	4.91e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ERCC2—prostate cancer	1.16e-06	4.87e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGF10—prostate cancer	1.15e-06	4.86e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NCOA1—prostate cancer	1.15e-06	4.84e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP1A1—prostate cancer	1.14e-06	4.81e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ADRB2—prostate cancer	1.14e-06	4.8e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ERCC2—prostate cancer	1.13e-06	4.77e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP19A1—prostate cancer	1.13e-06	4.77e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—LPL—prostate cancer	1.13e-06	4.75e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—KRAS—prostate cancer	1.12e-06	4.73e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—MAP2K1—prostate cancer	1.12e-06	4.72e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PDGFRB—prostate cancer	1.12e-06	4.71e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CD—prostate cancer	1.12e-06	4.69e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VAV3—prostate cancer	1.11e-06	4.69e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TGFBR2—prostate cancer	1.1e-06	4.62e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—RXRA—prostate cancer	1.09e-06	4.6e-05	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TP53—prostate cancer	1.09e-06	4.58e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—MTHFR—prostate cancer	1.09e-06	4.57e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERCC2—prostate cancer	1.08e-06	4.55e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ITPR1—prostate cancer	1.08e-06	4.54e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PPARA—prostate cancer	1.07e-06	4.49e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—MTHFR—prostate cancer	1.07e-06	4.49e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.06e-06	4.48e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERBB3—prostate cancer	1.06e-06	4.45e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FGFR2—prostate cancer	1.06e-06	4.45e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—COMT—prostate cancer	1.05e-06	4.43e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTP1—prostate cancer	1.05e-06	4.41e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PPARA—prostate cancer	1.05e-06	4.4e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IGF1R—prostate cancer	1.03e-06	4.35e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ITPR1—prostate cancer	1.03e-06	4.34e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PIK3CA—prostate cancer	1.03e-06	4.34e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—JAK2—prostate cancer	1.02e-06	4.3e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MTHFR—prostate cancer	1.02e-06	4.28e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.02e-06	4.27e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TERT—prostate cancer	1.01e-06	4.27e-05	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—AKT1—prostate cancer	1.01e-06	4.25e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CAV1—prostate cancer	1e-06	4.22e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—prostate cancer	9.99e-07	4.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—LPL—prostate cancer	9.9e-07	4.17e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CAV1—prostate cancer	9.84e-07	4.14e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PDGFRB—prostate cancer	9.82e-07	4.13e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—TYMS—prostate cancer	9.75e-07	4.1e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CB—prostate cancer	9.72e-07	4.09e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HIF1A—prostate cancer	9.7e-07	4.08e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTM1—prostate cancer	9.64e-07	4.06e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ITGB3—prostate cancer	9.57e-07	4.02e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—LPL—prostate cancer	9.46e-07	3.98e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	9.4e-07	3.95e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CAV1—prostate cancer	9.39e-07	3.95e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL8—prostate cancer	9.34e-07	3.93e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB3—prostate cancer	9.28e-07	3.9e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGFR2—prostate cancer	9.26e-07	3.9e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP1A1—prostate cancer	9.14e-07	3.84e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CG—prostate cancer	9.14e-07	3.84e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ERCC2—prostate cancer	9.07e-07	3.81e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CG—prostate cancer	8.96e-07	3.77e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL2—prostate cancer	8.93e-07	3.75e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TERT—prostate cancer	8.89e-07	3.74e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—BAD—prostate cancer	8.83e-07	3.71e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—INS—prostate cancer	8.65e-07	3.64e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—APC—prostate cancer	8.55e-07	3.6e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—MTHFR—prostate cancer	8.52e-07	3.58e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HIF1A—prostate cancer	8.51e-07	3.58e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—INS—prostate cancer	8.48e-07	3.57e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CREBBP—prostate cancer	8.47e-07	3.56e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGF—prostate cancer	8.45e-07	3.55e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IRS1—prostate cancer	8.45e-07	3.55e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—AKT1—prostate cancer	8.43e-07	3.55e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PPARA—prostate cancer	8.36e-07	3.52e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CREBBP—prostate cancer	8.31e-07	3.49e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—LEP—prostate cancer	8.3e-07	3.49e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CAV1—prostate cancer	8.23e-07	3.46e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—GSK3B—prostate cancer	8.2e-07	3.45e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KDR—prostate cancer	8.13e-07	3.42e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—INS—prostate cancer	8.09e-07	3.4e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CD—prostate cancer	8.03e-07	3.38e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ESR1—prostate cancer	7.93e-07	3.33e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CREBBP—prostate cancer	7.93e-07	3.33e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CD—prostate cancer	7.88e-07	3.31e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CAV1—prostate cancer	7.86e-07	3.31e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—BAD—prostate cancer	7.74e-07	3.25e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—NOS3—prostate cancer	7.59e-07	3.19e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MAP2K1—prostate cancer	7.57e-07	3.18e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CD—prostate cancer	7.52e-07	3.16e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.51e-07	3.16e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APC—prostate cancer	7.49e-07	3.15e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CG—prostate cancer	7.49e-07	3.15e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NOS3—prostate cancer	7.44e-07	3.13e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SERPINE1—prostate cancer	7.43e-07	3.13e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGF—prostate cancer	7.41e-07	3.12e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IRS1—prostate cancer	7.41e-07	3.12e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FGF2—prostate cancer	7.2e-07	3.03e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—GSK3B—prostate cancer	7.19e-07	3.02e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CG—prostate cancer	7.16e-07	3.01e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NOS3—prostate cancer	7.1e-07	2.98e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—INS—prostate cancer	7.09e-07	2.98e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CB—prostate cancer	7e-07	2.94e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CREBBP—prostate cancer	6.95e-07	2.92e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTGS2—prostate cancer	6.94e-07	2.92e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—JAK2—prostate cancer	6.9e-07	2.9e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CB—prostate cancer	6.87e-07	2.89e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IGF1—prostate cancer	6.86e-07	2.89e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EGFR—prostate cancer	6.83e-07	2.87e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTGS2—prostate cancer	6.8e-07	2.86e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—INS—prostate cancer	6.78e-07	2.85e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MDM2—prostate cancer	6.73e-07	2.83e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CREBBP—prostate cancer	6.64e-07	2.79e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERBB2—prostate cancer	6.64e-07	2.79e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAP2K1—prostate cancer	6.63e-07	2.79e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CD—prostate cancer	6.59e-07	2.77e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CB—prostate cancer	6.55e-07	2.76e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SERPINE1—prostate cancer	6.51e-07	2.74e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTGS2—prostate cancer	6.49e-07	2.73e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—prostate cancer	6.45e-07	2.71e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGF2—prostate cancer	6.31e-07	2.65e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CD—prostate cancer	6.29e-07	2.65e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NOS3—prostate cancer	6.22e-07	2.62e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1B—prostate cancer	6.15e-07	2.59e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTEN—prostate cancer	6.05e-07	2.54e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—JAK2—prostate cancer	6.05e-07	2.54e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NOS3—prostate cancer	5.94e-07	2.5e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTEN—prostate cancer	5.93e-07	2.5e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CA—prostate cancer	5.92e-07	2.49e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MDM2—prostate cancer	5.9e-07	2.48e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB2—prostate cancer	5.82e-07	2.45e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CTNNB1—prostate cancer	5.81e-07	2.44e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—EP300—prostate cancer	5.77e-07	2.43e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CB—prostate cancer	5.74e-07	2.41e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1A—prostate cancer	5.67e-07	2.39e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTEN—prostate cancer	5.66e-07	2.38e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—EP300—prostate cancer	5.66e-07	2.38e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL8—prostate cancer	5.52e-07	2.32e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CB—prostate cancer	5.49e-07	2.31e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTGS2—prostate cancer	5.44e-07	2.29e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EP300—prostate cancer	5.4e-07	2.27e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1B—prostate cancer	5.39e-07	2.27e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CASP3—prostate cancer	5.28e-07	2.22e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL2—prostate cancer	5.27e-07	2.22e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SRC—prostate cancer	5.25e-07	2.21e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6—prostate cancer	5.25e-07	2.21e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCND1—prostate cancer	5.14e-07	2.16e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CTNNB1—prostate cancer	5.09e-07	2.14e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—STAT3—prostate cancer	5.06e-07	2.13e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP9—prostate cancer	4.99e-07	2.1e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1A—prostate cancer	4.97e-07	2.09e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTEN—prostate cancer	4.96e-07	2.09e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AKT1—prostate cancer	4.84e-07	2.04e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTEN—prostate cancer	4.74e-07	1.99e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EP300—prostate cancer	4.73e-07	1.99e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MYC—prostate cancer	4.7e-07	1.98e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TGFB1—prostate cancer	4.69e-07	1.97e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGFR—prostate cancer	4.6e-07	1.94e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SRC—prostate cancer	4.6e-07	1.94e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—EP300—prostate cancer	4.52e-07	1.9e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—prostate cancer	4.48e-07	1.88e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STAT3—prostate cancer	4.44e-07	1.87e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—prostate cancer	4.35e-07	1.83e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CA—prostate cancer	4.27e-07	1.8e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CA—prostate cancer	4.19e-07	1.76e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MYC—prostate cancer	4.12e-07	1.73e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TGFB1—prostate cancer	4.11e-07	1.73e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGFR—prostate cancer	4.03e-07	1.7e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CA—prostate cancer	3.99e-07	1.68e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—prostate cancer	3.81e-07	1.6e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6—prostate cancer	3.54e-07	1.49e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CA—prostate cancer	3.5e-07	1.47e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKT1—prostate cancer	3.49e-07	1.47e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—AKT1—prostate cancer	3.42e-07	1.44e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—prostate cancer	3.39e-07	1.42e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CA—prostate cancer	3.34e-07	1.41e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—AKT1—prostate cancer	3.26e-07	1.37e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6—prostate cancer	3.1e-07	1.3e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKT1—prostate cancer	2.86e-07	1.2e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—AKT1—prostate cancer	2.73e-07	1.15e-05	CbGpPWpGaD
